Innventure, Inc. reported that seven senior management members and directors voluntarily forfeited a total of 435,168 shares of common stock. The shares were originally issued as earnout awards triggered by Milestone One, which required Accelsius to secure over $15 million in revenue from DarkNX. Although the Independent Committee had previously determined the milestone was achieved based on a binding purchase order with DarkNX, DarkNX subsequently informed Accelsius that the specific deployment site was unavailable and removed the project from its 2026 forecast. The Board decided the executives should forfeit these shares to align interests with shareholders pending resolution of the DarkNX deal. The canceled shares were processed by the transfer agent between September 8 and September 15, 2026. Innventure is a healthcare technology company that develops digital health solutions for chronic disease management.

Innventure announced a significant leadership overhaul and governance restructuring effective September 1, 2026. Dr. William Grieco assumes the role of Chief Executive Officer and director, replacing retiring CEO Gregory W. Haskell. Bruce Brown was appointed independent Chairman of the Board, succeeding Michael Otworth, while Suzanne Niemeyer resigned from the Board, reducing its size to eight directors. The company also launched a search for a new CFO following David Yablunosky's expected departure and announced Dr. John Scott's exit as Chief Strategy Officer. Concurrently, Innventure disclosed a putative securities class action complaint filed on August 28, 2026, alleging misleading statements regarding business operations during the period from November 17, 2025 to August 13, 2026. The company is also implementing cost reductions, lowering quarterly parent-level cash expenses from $7.5 million to $4.5 million and exploring strategic alternatives for its AeroFlexx subsidiary. Innventure operates as an industrial growth conglomerate that commercializes breakthrough technology solutions through its operating companies.

Innventure, Inc. announced that Chief Executive Officer and Class I director Gregory W. Haskell will retire effective October 1, 2026. Mr. Haskell will serve as an advisor through July 15, 2027, under a consulting agreement providing COBRA premium reimbursements and equity vesting. Dr. William Grieco, the current CEO of subsidiary Refinity Holdings, LLC, has been appointed as the new CEO and Class I director, effective October 1, 2026. Dr. Grieco's compensation includes a $550,000 annual base salary, a 100% target cash bonus, and an initial $1,000,000 restricted stock unit grant. He will also be eligible for annual long-term equity grants valued at approximately $1,500,000 starting in April 2027. Innventure, Inc. is a technology company focused on transforming plastic waste into chemical intermediaries.

Innventure, Inc. filed this Form 8-K/A to correct an error in its previous filing regarding the 2026 Annual Meeting of Stockholders held on June 17, 2026. The amendment corrects the name of a successful director nominee from John Hewitt to James O. Donnally. The voting results for Proposal 1 elected Bruce Brown, James O. Donnally, and Catriona Fallon as Class II directors for three-year terms expiring in 2029. Additionally, stockholders ratified the appointment of Withum Smith+Brown, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Innventure, Inc. is a company that operates in the technology or specialized services sector.